Dr Krishnan on the Evolving Role of Belantamab Mafodotin in Multiple Myeloma

The potential role of belantamab mafodotin in multiple myelomaПодробнее

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Final analysis of the DREAMM-2 trial: belantamab mafodotin for R/R multiple myelomaПодробнее

Evolution in myeloma therapyПодробнее

The evolving treatment landscape for multiple myelomaПодробнее

Dr. Rodriguez on Evolving Role of Small Molecules in Multiple MyelomaПодробнее

Evolution of the multiple myeloma therapeutic landscapeПодробнее

DREAMM-2: update on belantamab mafodotin in R/R myelomaПодробнее

DREAMM-2 & DREAMM-5: belantamab mafodotin for myelomaПодробнее

Current & emerging biomarkers in multiple myelomaПодробнее

MCRT Baltimore 2018: Evolution of Multiple Myeloma by Ivan Borrello, MDПодробнее

New insight into the biology of multiple myeloma: from clonal evolution to new treatment optionsПодробнее

Belantamab mafodotin and its place in myeloma treatmentПодробнее

The changing role of autoSCT in the treatment of multiple myeloma in the era of novel agentsПодробнее

The role of immunotherapy in multiple myelomaПодробнее

Promising clinical trials for multiple myeloma: KarMMa, CARTITUDE and EVOLVEПодробнее

Evolving understanding of multiple myelomaПодробнее

IMF Virtual Regional Community Workshop (RCW) - Pacific NorthwestПодробнее

Multiple myeloma: genomic evolutionПодробнее